Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma
This study has been completed.
Study NCT00204555   Information provided by University Hospital Tuebingen

First Received on September 13, 2005.   Last Updated on August 31, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Basal Cell
Additional conditions recognized in this trial
Carcinoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Imiquimod
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
Antineoplastic Agents
Interferon Inducers
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University Hospital Tuebingen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services